ClinicalTrials.gg
CompletedNCT01449162Updated Feb 10, 2021

Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral Corticosteroids

A Phase 3 interventional study of Masitinib and Placebo in Asthma, sponsored by AB Science. Completed at 8 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by AB Science · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2011, registered Oct 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 296 studies in Asthma with a site in France — 44 open to participants now, 57 under way, 8 of them phase 3. Asthma · France.

Enrollment
65th of 204
420 · median 209
Started
2011
with 11 others
Phase 3
73 of 296
6 open now
Registered
60th of 296
by date

Among the 296 studies in Asthma with a site in France, this one is the 65th largest by enrollment of the 204 interventional ones that give a count, is one of 12 that started in 2011, is one of 73 in phase 3, and was the 60th registered.

Asthma

4,846 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

44 of the 296 studies in Asthma with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 296 studies in Asthma with a site in France, or all of them as a file.
02

Study summary

The study objective is to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the treatment of patients with Severe Persistent Asthma treated with oral corticosteroids.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor. It is known that activation of inflammatory cells, such as mast cells, and fibrous tissue remodeling are associated with c-Kit, Lyn and PDGFR kinase signaling pathways; all key targets of masitinib. The objective of this study is to compare the efficacy and safety of masitinib at 6 mg/kg/day versus matched placebo in severe persistent asthma patients that is uncontrolled with oral corticosteroids. The primary outcome measure will be severe asthma exacerbation rate over duration of the treatment.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • severe persistent asthma
  • tyrosine kinase inhibitor
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. Patient with severe asthma and already treated with oral at a minimal daily dose of 7.5 mg prednisone or equivalent for at least 3 months prior to screening visit
  2. Patient treated with oral corticosteroids during at least one period of 21 days, from 1 year prior to screening to 3 months before screening
  3. Patient with no significant change in the regular asthma medication, no severe asthma exacerbation for at least 4 weeks prior to screening visit
  4. Non-smoker patient for at least 1 year and with a prior tobacco consumption \< 10 packs/year

Main exclusion criteria:

  1. Patient with active lung disease other than asthma (e.g. chronic bronchitis)
  2. Female patient who is pregnant or lactating
  3. Asthmatic patient still exposed to allergens or to triggering factors influencing asthma control
  4. Patient with history of acute infectious sinusitis or respiratory tract infection within 4 weeks prior to screening visit
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Masitinib as add-on to oral corticosteroids

    Participants receive masitinib (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids

    Drug: Masitinib

  • Placebo comparator
    Placebo as add-on to oral corticosteroids

    Participants receive placebo (6 mg/kg/day), given orally twice daily, as add-on to oral corticosteroids

    Drug: Placebo

Interventions

  • 6 mg/kg/day

    Also known as: AB1010

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Severe asthma exacerbation rate

    The number of severe asthma exacerbations over time frame of outcome measure

    Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months

Secondary outcomes

  1. Asthma exacerbation rate

    The number of asthma exacerbations over time frame of outcome measure

    Time frame: Duration of patient treatment exposure, assessed until withdrawal from study, study completion date, or for a maximum of 60 months

  2. ACQ Score

    Asthma Control Questionnaire (ACQ) Score

    Time frame: 36 weeks

07

Study locations

8 sites
  • Dr. Georgi Stranski University Hospital
    Pleven, 5800, Bulgaria
  • Hospital Polyclinic Melnik
    Mělník, Czechia
  • Hospital La Cavale Blanche
    Brest, 29609, France
  • l'Hopital Albert Calmette
    Lille, France
  • l'Hopital de la Croix Rousse
    Lyon, 69317, France
  • University of Debrecen Medical and Health Science Center
    Debrecen, 4032, Hungary
  • King George Hospital
    Hyderabad, 500068, India
  • Hospital Universitario Doctor Peset
    Valencia, 46017, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Nov 2019, 106 months.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 106 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2011
First posted
Oct 10, 2011
StartActual
Jan 2011
Primary completionActual
Nov 2019
CompletionActual
Nov 2019
Results delay requested
Mar 30, 2020
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01449162
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Oct 10, 2011
Start date
Jan 2011
Primary completion
Nov 2019
Completion
Nov 2019
Last update
Feb 10, 2021

Study contacts

Lavinia Davidescu, MD, PhD
principal investigator · University of Medicine and Pharmacy Oradea, Oradea, Romania

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion